Apogee Therapeutics, Inc. — Form 10-Q
Filed August 10, 2026 · analyzed by the Periodic Agent
10-Q
▲ Likely positive
significance 72/100
What the filing says
On May 26, 2026, Apogee Therapeutics sold revenue participation rights for its IL-13 antibody APG777 to Annapurna Aggregator L.P. (managed by Blackstone Life Sciences) for an upfront payment of $100 million, plus up to $300 million in tranched payments ($100M + $200M) contingent on clinical trial milestones, and up to $400 million in optional Tranche 4 funding. Apogee retains upfront cash while Annapurna receives tiered revenue percentages (0.9375%–2.5%+ depending on net sales tier) throughout a 15-year revenue payment term starting at first commercial sale.
Why this rating
Material near-term financing ($100M immediate, ~6% of market cap) de-risks APG777 development; significant upside if trials succeed and drug commercializes; modest drag on long-term revenue but preserves cash for operations.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.